183 related articles for article (PubMed ID: 37624862)
1. Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma.
Dittrich K; Yıldız-Altay Ü; Qutab F; Kwong DA; Rao Z; Nievez-Lozano SA; Gardner HL; Richmond JM; London CA
PLoS One; 2023; 18(8):e0290428. PubMed ID: 37624862
[TBL] [Abstract][Full Text] [Related]
2. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
3. Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).
Mudaliar MA; Haggart RD; Miele G; Sellar G; Tan KA; Goodlad JR; Milne E; Vail DM; Kurzman I; Crowther D; Argyle DJ
PLoS One; 2013; 8(9):e72591. PubMed ID: 24023754
[TBL] [Abstract][Full Text] [Related]
4. Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signature.
Licenziato L; Minoli L; Ala U; Marconato L; Fanelli A; Giannuzzi D; De Maria R; Iussich S; Orlando G; Bertoni F; Aresu L
Vet Pathol; 2023 May; 60(3):308-315. PubMed ID: 36951124
[TBL] [Abstract][Full Text] [Related]
5. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.
Richards KL; Motsinger-Reif AA; Chen HW; Fedoriw Y; Fan C; Nielsen DM; Small GW; Thomas R; Smith C; Dave SS; Perou CM; Breen M; Borst LB; Suter SE
Cancer Res; 2013 Aug; 73(16):5029-39. PubMed ID: 23783577
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood cell ratios as prognostic factors in canine diffuse large B-cell lymphoma treated with CHOP protocol.
Henriques J; Felisberto R; Constantino-Casas F; Cabeçadas J; Dobson J
Vet Comp Oncol; 2021 Jun; 19(2):242-252. PubMed ID: 33247533
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers.
Marconato L; Aresu L; Stefanello D; Comazzi S; Martini V; Ferrari R; Riondato F; Rouquet N; Frayssinet P; Sabattini S
J Immunother Cancer; 2019 Jun; 7(1):146. PubMed ID: 31174615
[TBL] [Abstract][Full Text] [Related]
10. Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.
Shi Y; Ding W; Gu W; Shen Y; Li H; Zheng Z; Zheng X; Liu Y; Ling Y
J Leukoc Biol; 2022 Dec; 112(6):1633-1648. PubMed ID: 36040107
[TBL] [Abstract][Full Text] [Related]
11. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
[TBL] [Abstract][Full Text] [Related]
12. Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma.
Panjwani MK; Atherton MJ; MaloneyHuss MA; Haran KP; Xiong A; Gupta M; Kulikovsaya I; Lacey SF; Mason NJ
Oncoimmunology; 2020; 9(1):1676615. PubMed ID: 32002286
[TBL] [Abstract][Full Text] [Related]
13. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
Mizuno T; Kato Y; Kaneko MK; Sakai Y; Shiga T; Kato M; Tsukui T; Takemoto H; Tokimasa A; Baba K; Nemoto Y; Sakai O; Igase M
Sci Rep; 2020 Jul; 10(1):11476. PubMed ID: 32651429
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY.
Sirivisoot S; Kasantikul T; Techangamsuwan S; Radtanakatikanon A; Chen K; Lin TY; Rungsipipat A
Sci Rep; 2022 Mar; 12(1):5120. PubMed ID: 35332215
[TBL] [Abstract][Full Text] [Related]
15. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
16. Improving outcomes for patients with diffuse large B-cell lymphoma.
Flowers CR; Sinha R; Vose JM
CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
18. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
19. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy.
Martini V; Aresu L; Riondato F; Marconato L; Cozzi M; Stefanello D; Comazzi S
Res Vet Sci; 2019 Aug; 125():130-135. PubMed ID: 31212200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
